Notably, a subgroup analysis suggested that the survival benefit is greater in patients with UM-IGHV genes, a finding replicated in other studies, logically suggesting that BTK inhibition is more effective in cases where the CLL cells have a higher BCR signalling capacity [2,3,36]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.